Back to News
Market Impact: 0.4
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio
Source: zacks.com
M&A & RestructuringHealthcare & BiotechCompany Fundamentals
Viatris (VTRS) is set to acquire Pacira BioSciences (PCRX) for $1.65 billion in cash. The deal would add two marketed pain therapies and a clinical-stage gene therapy candidate, expanding VTRS’s non-opioid pain portfolio.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
PCRX0.30
VTRS0.50
More News
- Gold Rises Over 1%; US Consumer Sentiment Falls
- Dow Gains Over 100 Points; Delta Air Lines Shares Fall After Q3 Results
- Verizon stock heads for worst day since 2002 as SpaceX U.S. network plans whack telcos
- Wall Street Week | Michigan Manufacturing, AI Debt Investments, Baby Bonds, Canadian Coal Fight
- OpenAI's revenue scare, Delta earnings, what investors think of a Starbucks-Chipotle deal and more in Morning Squawk
- Tesla drops 'Full Self-Driving' brand name in Europe after regulator pushback
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- State of M&A and Private Markets, June 2026: A $4.9 Trillion Rebound, Underwritten on Money That Never Got Cheaper
- Run Cost-Controlled Financial Research in AllMind Agent Studio